Agilent Technologies Upgrades Cerity CDS for Pharmaceutical QA/QC
News Dec 20, 2005
Agilent Technologies Inc. has announced the release of Cerity CDS A.02.03, a chromatography data system for pharmaceutical quality assurance/quality control laboratories, designed to enhance workflows and facilitate compliance of pharmaceutical QA/QC labs of all sizes.
"We’ve designed a complete package for today’s pharmaceutical QA/QC lab that adapts easily to laboratory workflow to optimize efficiency and productivity, while also providing close integration with other internal and external systems," said Gunter Nill, general manager, Pharma Solutions Business, Agilent Life Sciences and Chemical Analysis.
Cerity CDS is designed to offer fully automated validation tools for analytical hardware qualification and verification, as well as software qualification.
Cerity CDS offers many features to facilitate FDA 21 CFR Part 11 compliance, including version control, inherent data integrity and an automatic, fully-traceable audit trail to ensure that no records can be overwritten.
It provides for Level-4 instrument control, including security features such as active handshake, error checking, automated tracking of serial numbers and firmware revisions, and advanced diagnostics.
Cerity A.02.03 scales up seamlessly from standalone, single-user configurations to distributed multi-user, multi-instrument configurations for labs with 100 instruments or more.
"We’re protecting customers’ investments in Cerity for Pharmaceutical QA/QC by building on technology such as instrument control through LAN or Oracle-based data management," Nill added.
"Cerity CDS for Pharmaceutical QA/QC also provides for integration of leading-edge technologies."
Customers with a current Agilent Support Contract will receive a free upgrade to Cerity CDS A.02.03 software.
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Worldwide Clinical Trials Receives 2018 CRO Leadership AwardsNews
Life Science Leader and Industry Standard Research assess 70 contract research organizations, honoring Worldwide Clinical Trials for fifth consecutive year.READ MORE
WuXi Biologics to Invest in Biologics Manufacturing Facility in SingaporeNews
WuXi Biologics' first overseas site in Asia.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018